Validation of the health-related quality of life instrument with 8 items for assessing health-related quality of life in patients with oropharyngeal cancer: a comparison with the EQ-5D-5L

验证包含8个条目的健康相关生活质量量表在评估口咽癌患者健康相关生活质量方面的有效性:与EQ-5D-5L的比较

阅读:1

Abstract

BACKGROUND: To overcome the limitations of existing health-related quality of life (HRQoL) instruments, the HRQoL Instrument with 8 Items (HINT-8) was developed for the Korean population. We aimed to evaluate the validity, interrater reliability, and agreement of the HINT-8 compared to the EQ-5D-5 L among patients with oropharyngeal cancer (OPC). METHODS: A total of 327 patients with OPC aged ≥ 19 years who received treatment at 14 hospitals in South Korea were recruited between August 2023 and February 2024. HRQoL was assessed using the two instruments. The psychometric evaluation included analyses of validity (convergent and known-group validity), agreement (intraclass correlation coefficient and Bland-Altman analysis), and reliability (internal consistency measured by Cronbach's alpha). The ceiling effects and score distributions were also examined. RESULTS: In total, 299 respondents were included in the final analysis. Both instruments demonstrated high internal consistency (HINT-8: α = 0.872; EQ-5D-5 L: α = 0.845) and good agreement (intraclass correlation coefficient [ICC] = 0.80; 95% confidence interval [CI]: 0.76-0.84). The convergent validity was supported by strong correlations between the HINT-8 index and both the EQ-5D-5 L index (r = 0.805) and EQ VAS (r = 0.715). The ceiling effect of HINT-8 (12.7%) was substantially lower than the EQ-5D-5 L (32.8%). CONCLUSIONS: The HINT-8 is a valid, reliable, and responsive instrument for measuring HRQoL in patients with oropharyngeal cancer. These findings suggest that HINT-8 can serve as a valuable complementary instrument to the EQ-5D-5 L.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。